BOCA RATON, FL -- (MARKET WIRE) -- November 28, 2006 -- Vicor Technologies, Inc., developer of the Vicor PD2i Cardiac Analyzer, a patented device utilized in the risk stratification of patients for Sudden Cardiac Death (SCD), announced that it had completed the initiation process for two of the initial five clinical sites selected for its VITAL Trial. The Company also has enrolled two patients in the VITAL Trial. The two sites are the VA Hospital and Massachusetts General Hospital, both in Boston, MA. These sites are now actively screening additional patients for enrollment in the VITAL Trial.
